Agenus (AGEN)
(Delayed Data from NSDQ)
$5.09 USD
-0.19 (-3.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.07 -0.02 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGEN 5.09 -0.19(-3.60%)
Will AGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGEN
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Other News for AGEN
Agenus, Inc. (AGEN) Q2 2024 Earnings Call Transcript
Agenus Inc. 2024 Q2 - Results - Earnings Call Presentation
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024
Agenus Hold Rating: Balancing Phase 2 Progress with Regulatory Challenges and Uncertainty
Agenus reports Q2 EPS ($2.52) vs. ($3.93) last year